The Value of TAKECHARGE

The original prototype of TAKECHARGE was tested in 1983 in clinical trials at the University of Virginia.  This was one of the first studies done to show that health improvement was possible.  It showed positive improvements could e be achieved with blood cholesterol, blood pressure and blood sugars.  With this study, the concept and proof of health promotion and disease prevention was applied to the TAKECHARGE system.

An Overview
Prior to the introduction of TAKECHARGE, a clinical study was conducted at a major eastern research university to determine the efficacy and health impact of the original formula of TAKECHARGE in a weight-loss program.  The following is a general overview of teh study and its results.  A more thorough presentation of the study is available from Ultra Nutrition International, Inc. 

Program Number: 06.003

Project Title: Nutritional and Metabolic Effects of Reducing Diets

Purpose of the Clinical Study
To determine the efficacy and health impact of the TAKECHARGE product and program.

Facts on the Participants
Number of participants: 60
Average age: 39.7 years
Youngest: 23 years
Oldest 73 years
Mixture of males and females

Actual Weight Loss
Time period: 4 weeks
Greatest weight loss (male): 24.5 lbs
Greatest weight loss (female): 17.5 lbs
Average weight loss (male): 17.05 lbs
Average weight loss (female): 10.0 lbs

Completion Success
It's significant to note that in documented obesity studies, participants in a weight-loss program more than three weeks have a success rate of about 20%. In contrast, the TAKECHARGE Program had a success completion rate of over 90%.  Even more significantly, the longer the participants were on the TAKECHARGE Program, the more enthusiastic they became.

Electrolyte Levels
These are the most significant signals to monitor during a weight-loss program to determine its actual safety.  Low electrolyte levels can result in irregular heartbeats which can frequently be fatal. While other minerals are important, p[resented here are the most important electrolytes to monitor: potassium and sodium.

Potassium
Beginning average: 4.29 mEq/l
End of study average: 4.02 mEq/l
Normal ranges are 135 mEq/100 ml to 148 mEq/100 ml.  Again, no participant's sodium level was ever outside the normal range during the entire clinical study.

Blood Pressure
Beginning average: 127.56 (S)/80.50 (D)
End of study average: 113.78 (S)/74.28 (D)
The systolic was down 14 mm hg and the diastolic was down by 6 mm hg. Many of the participants at the start of the study measured in the hypertensive range (pressure greater than 140/90). All  ended in the normal range.

Cholesterol
Beginning average: 207.39 mg/100 ml
End of study average: 178.22 mg/100 ml
The normal risk range is 150 mg/100 ml to 225 mg/100 ml.  Cholesterol went down 29 points or 14.1% during the study for the average of the group.  Lowering the cholesterol level reduces the risk of heart disease.

Triglycerides
Beginning average: 178.88 mg/100 ml
End of study average: 147.77 mg/100 ml
The normal risk range is 10 mg/100 ml to 160 mg/100 ml. Triglycerides went down 31 points or 17.4% during the study for the average of the group.  Lowering the triglyceride level reduces the risk of heart disease.

Fasting Blood Glucose
Beginning average: 101.11 mg/100 ml
End of study average: 96.44 mg/100 ml
The normal risk range is 70 mg/100 ml to 110 mg/100 ml. A number of participants were outside this range at the start of the study high glucose levels in the diabetic range.  All participants were in the normal range at the study's completion. Average glucose was down 5%. The most significant decline by any participant was a decrease of 8 mg/100 ml in only 4 weeks.